Author Correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA
| Autor: | James Trevor Oswald, Mohammad Ariful Islam, Morteza Mahmoudi, Omid C. Farokhzad, Jessalyn M. Ubellacker, Gha Young Lee, Kun Zhou, Jinjun Shi, Wuji Cao, Robert Langer, Meshkat Dinarvand, Wei Tao, Bruce R. Zetter, Harshal Zope, Daniel Aum, Michael Lim, Mi Kyung Yu, Yingjie Xu, Philip W. Kantoff |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Growth suppression
Competing interests biology 010405 organic chemistry Biomedical Engineering Medicine (miscellaneous) Bioengineering Context (language use) Safety Monitoring Boards 010402 general chemistry 01 natural sciences 0104 chemical sciences Computer Science Applications Management New england biology.protein PTEN Business Biotechnology |
| Zdroj: | Nature Biomedical Engineering. 2:968-968 |
| ISSN: | 2157-846X |
| DOI: | 10.1038/s41551-018-0331-x |
| Popis: | The authors wish to add the following sentence into the 'Competing interests' section of this Article: "P.W.K. has investment interest in Context Therapeutics LLC, DRGT, Placon, Seer Biosciences and Tarveda Therapeutics, is a company board member for Context Therapeutics LLC, is a consultant and scientific advisory board member for BIND Biosciences, Inc., BN Immunotherapeutics, DRGT, GE Healthcare, Janssen, Metamark, New England Research Institutes, Inc., OncoCellMDX, Progenity, Sanofi, Seer Biosciences, Tarveda Therapeutics and Thermo Fisher, and serves on data safety monitoring boards for Genentech/Roche and Merck." This has now been included. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink